Page 5 - Armata Pharmaceuticals Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Armata pharmaceuticals inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Armata Pharmaceuticals Inc Today - Breaking & Trending Today

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific. ....

United States , France General , Pierre Kyme , Deborah Birx , Deborahl Birx , Joyce Allaire , Prnewswire Armata Pharmaceuticals Inc , Armata Pharmaceuticals Inc , Defense Health Agency , Technology Enterprise Consortium , Warfighter Medical Research Program , Us Department Of Defense , Lifesci Advisors , Recent Developments , Innoviva Board , Chief Executive , World Conference , Targeting Phage Therapy , Medical Technology Enterprise Consortium , Joint Warfighter Medical Research , Armata Pharmaceuticals , Private Securities Litigation Reform Act , Annual Report , Sci Advisors , Consolidated Statements , Months Ended June ,

ARMP Stock Price | Armata Pharmaceuticals Inc. Stock Quote (U.S.: NYSE American)

ARMP | Complete Armata Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ....

Los Angeles , Armata Pharmaceuticals Inc , Armata Pharmaceuticals , Rmp Analyst Estimates , Rmp Earnings Estimates , Rmp Share Estimates , Rmp Analyst Recommendations , Rmp Ratings , Rmata Pharmaceuticals Inc Analyst Estimates , Rmata Pharmaceuticals Inc Earnings Estimates , Rmata Pharmaceuticals Inc Analyst Recommendations , Rmata Pharmaceuticals Inc Analyst Ratings ,

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 688.3% in July

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 688.3% in July
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Armata Pharmaceuticals Inc , News Ratings For Armata Pharmaceuticals Daily , Armata Pharmaceuticals Stock Performance , Northern Trust Corp , Renaissance Technologies , Vanguard Group Inc , Institutional Investors Weigh In On Armata Pharmaceuticals , Armata Pharmaceuticals , Get Free Report , Trust Corp , Street Group , Vanguard Group , Armata Pharmaceuticals Daily ,

Armata Pharmaceuticals (ARMP) to Release Earnings on Wednesday

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) is scheduled to issue its quarterly earnings data on Wednesday, August 9th. Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last posted its quarterly earnings data on Thursday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). The […] ....

Earnings History For Armata Pharmaceuticals , Armata Pharmaceuticals Inc , Armata Pharmaceuticals , Institutional Investors Weigh In On Armata Pharmaceuticals , News Ratings For Armata Pharmaceuticals Daily , Vanguard Group Inc , Renaissance Technologies , Armata Pharmaceuticals Stock Performance , Northern Trust Corp , Get Free Report , Trust Corp , Jane Street Group , Armata Pharmaceuticals Daily , Nyseamerican Armp ,

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023

Received FDA approval for XACDURO® for treatment of. ....

Acinetobacter Baumannii Calcoaceticus , Pavel Raifeld , Deborah Birx , Securities Exchange , Exchange Commission , Glaxo Group Limited , Theravance Respiratory Company , Jolla Pharmaceutical Company , Innoviva Inc , Armata Pharmaceuticals Inc , Chief Executive Officer , Innoviva Strategic Opportunities , Armata Pharmaceuticals , Innoviva Board , Chief Executive , Innoviva Specialty Therapeutics , Long Acting Beta , Collaboration Agreement , Entasis Therapeutics , Private Securities Litigation Reform Act , Securities Exchange Act , Financial Condition , Annual Report , Quarterly Reports , Consolidated Statements , Months Ended June ,